Research & Development

Novartis offers to buy LFB group company CellforCure

Novartis has offered to acquire LFB group company CellforCure, which is specialized in the development of advanced therapy drugs.

Gilead, Agenus collaborate on immuno-oncology therapies development

Gilead Sciences and Agenus have entered into an immuno-oncology (I-O) partnership to develop and commercialize up to five novel immuno-oncology therapies.

Gilead, Scholar Rock to develop therapies for fibrotic diseases

Gilead Sciences and Scholar Rock have formed a collaboration to discover and develop highly specific inhibitors of transforming growth factor beta (TGFβ) activation for the treatment of fibrotic diseases.

DelSiTech, Innovare to develop long acting HIV therapy

Finland-based DelSiTech and Mexican pharma company Innovare R&D have signed a world-wide, exclusive license agreement for the use of the former’s Silica Matrix drug delivery platform in the development and commercialization of a long acting HIV therapy.

Amgen, Molecular Partners form immuno-oncology collaboration

Amgen and Molecular Partners have announced a collaboration and license agreement for the clinical development and commercialization of MP0310 (FAP x 4-1BB).

Fuji Pharma acquires minority stake in Alvotech

Japan-based Fuji Pharma has acquired a 4.2% stake in biopharmaceutical firm Alvotech for around $50m.

C4XD, Horizon to develop synthetic lethality targets in oncology

C4X Discovery (C4XD) and UK-based gene editing company Horizon Discovery Group have forged an exclusive target discovery partnership in oncology.

Innovent, Incyte sign collaboration deal for three clinical-stage product candidates

Incyte and Innovent Biologics have entered into a strategic collaboration agreement for three clinical-stage product candidates discovered and developed by Incyte.

Bausch Health signs stalking horse agreement to buy Synergy Pharmaceuticals

Bausch Health Companies has signed an agreement to acquire certain assets of Synergy Pharmaceuticals in a transaction valued at around $200m plus certain assumed liabilities.